GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.

HTP, Chromium and More Now Available to Help Promote Appetite Control and Metabolic BalanceNew York, June 24, 2025 (GLOBE ...

Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.

Semaglutide injections are helping you lose weight-but if yours isn't FDA-approved (and a lot of them aren't), it could be ...

Axios Visuals Women are being prescribed GLP-1 weight-loss drugs at higher rates than men, new data shows. Why it matters: This is another cultural moment when women, especially those approaching ...